Introduction
Sleep is a natural biological and physiological phenomenon, and adequate sleep is critical for maintaining good health and well-being. Sleep disorders may lead to undermined physical and mental functioning, chronic pain, respiratory failure, obesity, stress, and anxiety. 1 Hospitalized patients require longer periods of high-quality sleep to promote faster recovery. However, the quality of sleep is often overlooked in the inpatient environment, where treatment and care are prioritized over quality sleep. 2 A majority of patients with cancer experience sleep disorders to varying degrees throughout the treatment process. Patients with cancer who receive anti-cancer treatment experience particularly severe sleep disorders during treatment; these disorders are also exacerbated as their treatment is prolonged. 3
Hematopoietic stem cell transplantation (HSCT) can be divided into two ways: autologous and allogenic. Auto transplantation is the transplanting of one's hematopoietic stem cells, which have been collected in advance, and allogenic transplantation is the transplanting of another's. Patients who receive HSCT are hospitalized for 3–4 weeks on average and often experience emotional distress, such as frustration, anxiety, and isolation, as a result of being separated from their families for isolation treatment during hospitalization. 4 The intense anti-cancer treatment, total radiation therapy, and side effects of HSCT are factors that contribute to disrupted sleep during hospitalization. 5 , 6 Upon being admitted to the hospital, patients with HSCT receive high-dosage of chemotherapy and a large amount of intravenous (IV) fluids during a roughly 1-week pre-transplantation conditioning period, and often experience side effects such as infection, gastrointestinal disorders, and pain during the immunosuppressed period, leading to sleep disorders. 5 Treatment-related sleep disturbance factors such frequent visits with medical staff, and frequent use of toilets due to large amounts of fluid injection interfere with the sleep of transplant patients. 5 Previous studies on patients with HSCT reported that 70%–80% of patients experienced sleep disruption and disorders during hospitalization and that 26% of patients were clinically diagnosed with insomnia. 7 , 8 Sleep disorders in patients with HSCT can reduce their quality of life, cause tumor-related fatigue and a weakened immune system, diminish their cognitive function, exacerbate depression and anxiety, and in the worst cases may negatively affect the transplantation outcomes due to an increased inflammatory response. 6 , 9 , 10
Various objective and subjective measurement tools have been developed to evaluate sleep disorders. On one hand, subjective self-reporting tools have traditionally been used to measure sleep disorders. On the other hand, objective physiological methods such as actigraphy have been recommended to identify sleep disorders and understand the various characteristics of sleep. 11 It would be ideal to use both subjective and objective measures to complement each other because patients’ self-reporting may not be sufficient to understand the overall sleep patterns. 8
In a previous study that investigated the extent of sleep problems among patients with HSCT 2 weeks after being hospitalized in the transplantation ward, 26% of patients experienced clinical insomnia and 74% of the patients had at least mild insomnia. 7 Another study that analyzed patients’ sleep quality during the immunosuppressed period reported that a majority of the patients showed sleep deprivation and irregular sleep patterns, which were highly correlated with the number of days hospitalized. 8 The same study reported that sleep deprivation and irregular sleep patterns were more prominent in objectively measured data than in subjectively perceived data reported by patients. 8
Previous studies show that most sleep quality research on patients undergoing HSCT used self-reporting measures, while no study used both objective and subjective methods to measure sleep patterns and compare the results. The present study used actigraphy as an objective measure together with the self-reported Insomnia Severity Index (ISI) as a subjective measure to evaluate the quantity and quality of sleep and investigated the differences between the two sets of results.
Methods
Design
This descriptive survey-based study measured sleep time and efficiency among patients undergoing HSCT in each transplantation period using objective and subjective measures and compared the results obtained using the two methods.
Participants
Forty participants were recruited from the HSCT ward of a tertiary hospital in Seoul between June 2019 and June 2020. The sample size was calculated using the G∗Power 3.1 program. The sample size of 40 participants was determined based on preceding studies with an effect size of 0.5, significance level (α) of 0.05, and statistical power (1-β) of 0.80 for analysis of variance (ANOVA), and considering a 10% drop-out rate. Participants were selected from patients who understood the purpose of this study and voluntarily agreed to participate. The specific criteria for selecting participants are listed below: (1) Patients aged 19 and above undergoing HSCT due to leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome, amyloidosis, aplastic anemia, or other rare blood disorders (2) Patients who were able to communicate and understand the questionnaire sufficiently to provide responses
Patients who received total-body irradiation treatment as a pretreatment had been receiving mental health treatment due to existing sleep problems or taking psychiatric drugs daily to induce sleep, were moved to the intensive care unit from the transplantation unit due to an aggravated condition, or had experienced mental or neurological changes such as depression and delirium during their hospitalization were excluded from the study, as these conditions may have impacted the results.
Outcome measurements
Objective measurements
Actigraphy (Actigraphy-Spectrum™): Actigraphy is a simple-to-use, cost-effective method that is more appropriate than polysomnography for measuring sleep patterns for multiple days. 12 The actigraph includes a multi-directional accelerometer that detects motion, which distinguishes sleep and arousal according to the level of motion worn on the wrist. Data from the actigraph can be converted into a format which allows for processing with the Actiware analysis software. 13 Actiware software uses algorithms to process data based on one of three actiware sleep-wake threshold settings (Low, Medium and High). According to Madisen et al., ’s 2015 systematic review, it can be seen that actigraphy was used in a number of studies to examine the quality of sleep-in cancer patients. 2
Actigraphy was used to measure total sleep time, sleep efficiency, and wake after sleep onset. Total sleep time referred to the duration from sleep onset to offset. The average recommended sleep time per day for adults is 7–8 h. Sleep onset latency is the starting point of the first awake state of 1 min or less during a 20-min sleep state in the actigraphy data and the offset period is the last point recorded as the sleep state. Sleep efficiency denotes the percentage of total sleep time during the total duration of the sleep episode. The duration of the sleep episode is the total of sleep onset latency, total sleep time, wakefulness after sleep onset (WASO), and time attempting to sleep after final awakening. 14 A sleep efficiency of at least 80% is considered to be an indicator of adequate sleep. 15 The average WASO for adults without insomnia is 42 min out of 7 h (ie., 0.7 h or less). 15 Indicators such as total sleep time, sleep efficiency, and WASO are all transformed into analog electric signals based on the movements of the participants, and then transformed into digital signals through actigraphy programs, generating graphs and numerical data. 16
Subjective measurements
The ISI is a patient self-reporting tool for subjective sleep patterns that consists of seven questions regarding difficulty falling asleep, difficulty staying asleep, problems waking up too early, satisfaction with current sleep patterns, interference with daily functioning, anxiety about insomnia, and the level of sleep problems that are noticeable to others. 17 The ISI survey requires a relatively short time to complete (within 3 min) and is easy to use as a measurement of sleep quality over a short period of time.
Each question is scored with a Likert scale between 0 and 4. The total score can range from 0 to 28, with a higher score indicating a higher level of insomnia. 17 The results are classified into four categories according to the total score: 0–7 = no clinically significant insomnia, 8–14 = subthreshold insomnia, 15–21 = clinical insomnia (moderate severity), and 22–28 = clinical insomnia (severe). 17 The sleep efficiency measured by actigraphy means that the higher the score, the better the quality of sleep. But the ISI result value means that the higher the score, the worse the quality of sleep. Therefore, for the ease of comparison, the ISI result was inversely transformed so that the higher the ISI score, the higher the quality of sleep. The reversed total score of 0–19 indicated moderate to severe insomnia.
ISI was originally designed to evaluate sleep patterns in the past month, but in this study, it was confirmed that it could be used even if the period of 1 month was reduced to the period of 3 days with the approval of the developer. Therefore, the remaining period excluding the period before hospitalization (T1) was adjusted to 3 days. The Cronbach alpha of ISI was 0.92 by the scale developer 17 and 0.78 in this study.
Data collection and procedures
Researchers recruited participants from their affiliated hospital among inpatients with scheduled HSCT or patients hospitalized for transplantation and asked them whether they were willing to participate in the study after explaining the purpose and procedures of the study. The researchers conducted the study among patients who expressed willingness to participate and signed a written consent form. And a reward of 30,000 won was provided to the study participants.
Data on participants’ demographic and disease-related characteristics were collected based on their medical records. The participants were asked to complete the ISI on the day of hospitalization to understand their pre-treatment sleep efficiency (T1). Changes in sleep patterns after being hospitalized were measured in three different periods: the conditioning period (the period of receiving anti-cancer treatment, 2–3 days prior to transplantation: T2), the immunosuppressed period (absolute neutrophil count of 500/mm 3 or less, 4–8 days after transplantation: T3), and the engraftment period (absolute neutrophil count of 1000/mm 3 or higher, at discharge: T4).
The ISI was administered each time the actigraph unit was removed; therefore, objective sleep quality was measured a total of three times using actigraphy and subjective sleep quality was measured four times using the ISI (including baseline). At each period, participants started wearing the actigraphy unit on their non-dominant wrist at noon and removed it 48 h later at noon. In addition, the subjects were asked to keep a sleep diary. The sleep log was recorded directly after waking up at a time when the subject thought he had slept within 48 h of wearing the actigraphy. And subjectively perceived sleep time was also measured through one-on-one interviews and records of when they woke up in the morning.
Data analysis
The collected data were processed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Frequencies and percentages were calculated for participants' general characteristics and disease-related characteristics, and the average and standard deviation were estimated for objective and subjective sleep patterns by transplantation period. Objective sleep patterns measured with actigraphy were analyzed using Actiware. Repeated-measures ANOVA was used to compare the differences between objective and subjective values in total sleep time and sleep efficiency in each period. In this study, Cronbach's alpha was calculated for the reliability analysis, and the significance level was 0.05 or less.
Ethical considerations
Data collection was carried out after obtaining approval by the Institutional Review Board of the tertiary hospital in Seoul with which the researchers were affiliated (Approval No. 2019-05-014). The content and purpose of the study, the advantages and disadvantages of participating, and the fact that the results of this study would be used only for the purpose of this study were explained to the participants. The participants signed a written consent form after being explained that their anonymity and confidentiality would be protected, that their participation was voluntary and that they could decide to withdraw at any time. The collected data were stored and managed in a place that could only be accessed by researchers after deleting all information that could be used to identify individuals. The data will be discarded after keeping them for the stipulated period by the IRB upon completion of the study.
Results
General and disease-related characteristics of the participants
The participants consisted of 23 men (57.5%) and 17 women (42.5%), with a mean age of 52.6 years. A majority were diagnosed with lymphoma ( n = 18, 45.0%); 25 participants (62.5%) received autologous transplantation and 15 participants (37.5%) received allogeneic transplantation. Most patients ( n = 26, 65.0%) were staying in a room shared by five persons, while the others were in single rooms ( n = 14, 35.0%). All but one participant ( n = 39, 97.5%) had been hospitalized previously ( Table 1 ). Table 1 Demographic and disease-related characteristics of the HSCT patients ( n = 40). Table 1 Characteristics Categories n (%) Gender Male 23 (57.5) Female 17 (42.5) Age (year) (Mean = 52.6) ≤ 39 6 (15.0) 40–49 6 (15.0) 50–59 16 (40.0) 60–69 12 (30.0) Diagnosis Acute myeloid leukemia 9 (22.5) Acute lymphocytic leukemia 2 (5.0) Myelodysplastic syndrome 2 (5.0) Multiple myeloma 8 (20.0) Lymphoma 18 (45.0) Amyloidosis 1 (2.5) Marital status Married 37 (92.5) Never married 3 (7.5) Religion Yes 29 (72.5) No 11 (27.5) Type of transplantation Autologous 25 (62.5) Allogenic 15 (37.5) Type of rooms Single 14 (35.0) Shared 26 (65.0) Hospitalization experience Yes 39 (97.5) No 1 (2.5) HSCT, hematopoietic stem cell transplantation.
Table 1
Demographic and disease-related characteristics of the HSCT patients ( n = 40).
HSCT, hematopoietic stem cell transplantation.
| Characteristics | Categories | n (%) |
| Gender | ||
| Male | 23 (57.5) | |
| Female | 17 (42.5) | |
| Age (year) (Mean = 52.6) | ||
| ≤ 39 | 6 (15.0) | |
| 40–49 | 6 (15.0) | |
| 50–59 | 16 (40.0) | |
| 60–69 | 12 (30.0) | |
| Diagnosis | ||
| Acute myeloid leukemia | 9 (22.5) | |
| Acute lymphocytic leukemia | 2 (5.0) | |
| Myelodysplastic syndrome | 2 (5.0) | |
| Multiple myeloma | 8 (20.0) | |
| Lymphoma | 18 (45.0) | |
| Amyloidosis | 1 (2.5) | |
| Marital status | ||
| Married | 37 (92.5) | |
| Never married | 3 (7.5) | |
| Religion | ||
| Yes | 29 (72.5) | |
| No | 11 (27.5) | |
| Type of transplantation | ||
| Autologous | 25 (62.5) | |
| Allogenic | 15 (37.5) | |
| Type of rooms | ||
| Single | 14 (35.0) | |
| Shared | 26 (65.0) | |
| Hospitalization experience | ||
| Yes | 39 (97.5) | |
| No | 1 (2.5) |
Changes in sleep patterns by HSCT periods
Objective results of sleep patterns
The mean total sleep time, efficiency, and WASO measured by actigraphy in each HSCT period are illustrated in Table 2 . The total sleep time was the lowest during T2 (the conditioning period) compared to T3 (the immunosuppressed period) and T4 (the engraftment period), and sleep efficiency was the highest at 77.28% during T3 ( Table 2 ). The average WASO was the highest at 1.39 h in T2 and the lowest at 0.71 h in T3 ( Table 2 ). Table 2 Objective sleep time, efficiency and WASO by actigraphy according to the HSCT periods ( n = 40). Table 2 T2 T3 T4 Total (Mean ± SD) (Mean ± SD) (Mean ± SD) (Mean ± SD) Sleep time (h) 4.28 ± 1.43 5.28 ± 1.41 5.33 ± 1.82 4.96 ± 1.63 Sleep efficiency (%) 64.35 ± 11.38 77.28 ± 10.07 75.24 ± 10.44 72.29 ± 11.98 WASO (h) 1.39 ± 0.81 0.71 ± 0.28 1.16 ± 0.75 1.10 ± 0.71 HSCT, hematopoietic stem cell transplantation; T2, conditioning period; T3, immunosuppressed period; T4, engraftment period; Sleep time, total sleep time per day; Sleep efficiency, percentage of total sleep time during the total duration of the sleep episode; WASO, Wakefulness after sleep onset.
Table 2
Objective sleep time, efficiency and WASO by actigraphy according to the HSCT periods ( n = 40).
HSCT, hematopoietic stem cell transplantation; T2, conditioning period; T3, immunosuppressed period; T4, engraftment period; Sleep time, total sleep time per day; Sleep efficiency, percentage of total sleep time during the total duration of the sleep episode; WASO, Wakefulness after sleep onset.
| T2 | T3 | T4 | Total | |
| (Mean ± SD) | (Mean ± SD) | (Mean ± SD) | (Mean ± SD) | |
| Sleep time (h) | 4.28 ± 1.43 | 5.28 ± 1.41 | 5.33 ± 1.82 | 4.96 ± 1.63 |
| Sleep efficiency (%) | 64.35 ± 11.38 | 77.28 ± 10.07 | 75.24 ± 10.44 | 72.29 ± 11.98 |
| WASO (h) | 1.39 ± 0.81 | 0.71 ± 0.28 | 1.16 ± 0.75 | 1.10 ± 0.71 |
Subjective results of sleep patterns
The mean ISI at T1 did not indicate insomnia, but most participants developed moderate or higher insomnia during T2, where the reversed ISI scores were all 19 and lower ( Table 3 ). The quality of sleep was lowest during T3 and started to recover as they moved on to T4 ( Table 3 ). Table 3 Subjective sleep time by sleep diary and subjective sleep efficiency by ISI according to the HSCT periods ( n = 40). Table 3 Item T1 T2 T3 T4 Total (Mean ± SD) (Mean ± SD) (Mean ± SD) (Mean ± SD) (Mean ± SD) ISI scores∗ 23.43 ± 5.5 17.28 ± 6.57 16.55 ± 5.54 18.77 ± 5.50 19.00 ± 6.33 % ISI scores∗∗ 80.60 ± 18.94 59.57 ± 22.67 57.07 ± 19.11 64.74 ± 18.99 65.49 ± 21.83 HSCT, hematopoietic stem cell transplantation; T1, at admission time; T2, conditioning period; T3, immunosuppressed period; T4, engraftment period; ISI, Insomnia Severity Index; ∗reversed ISI scores; ∗∗ converted "reversed ISI scores" into a percentage.
Table 3
Subjective sleep time by sleep diary and subjective sleep efficiency by ISI according to the HSCT periods ( n = 40).
HSCT, hematopoietic stem cell transplantation; T1, at admission time; T2, conditioning period; T3, immunosuppressed period; T4, engraftment period; ISI, Insomnia Severity Index; ∗reversed ISI scores; ∗∗ converted "reversed ISI scores" into a percentage.
| Item | T1 | T2 | T3 | T4 | Total |
| (Mean ± SD) | (Mean ± SD) | (Mean ± SD) | (Mean ± SD) | (Mean ± SD) | |
| ISI scores∗ | 23.43 ± 5.5 | 17.28 ± 6.57 | 16.55 ± 5.54 | 18.77 ± 5.50 | 19.00 ± 6.33 |
| % ISI scores∗∗ | 80.60 ± 18.94 | 59.57 ± 22.67 | 57.07 ± 19.11 | 64.74 ± 18.99 | 65.49 ± 21.83 |
Comparison of objective and subjective sleep time
As a result of the Shapiro-Wilks test for normality test and repeated measurement analysis, the p value was 0.05 or more, and as a result of the Mauchly test for the sphericity test, the value for sphericity test was less than 0.05, so a value assumed for sphericity test was used. The total sleep times were significantly different by the period after accounting for the differences in measurement methods ( P < 0.001), while there were no significant differences in the results between objective and subjective sleep time ( P = 0.414). There were no interactions between the different methods over time ( P = 0.345) ( Table 4 ; Fig. 1 ). Table 4 Repeated measures ANOVA of objective and subjective sleep time ( n = 40). Table 4 Variables T2 T3 T4 Sources F P (Mean ± SD) (Mean ± SD) (Mean ± SD) Objective (h) 4.28 ± 1.43 5.28 ± 1.41 5.33 ± 1.82 Group 0.674 0.414 Subjective (h) 3.86 ± 1.51 4.95 ± 1.38 5.45 ± 1.63 Time 24.668 0.000∗∗∗ t ( P ) 0.37 (0.709) 1.78 (0.083) 1.33 (0.998) Group∗Time 1.072 0.345 T2, conditioning period; T3, immunosuppressed period; T4, engraftment period; objective, data from actigraphy, subjective: data from ISI, ∗∗∗ P < 0.001. Fig. 1 Repeated measures ANOVA comparisons over the phase of HSCT. ANOVA, analysis of variance; HSCT, hematopoietic stem cell transplantation; T2, conditioning period; T3, immunosuppressed period; T4, engraftment period. Fig. 1
Table 4
Repeated measures ANOVA of objective and subjective sleep time ( n = 40).
T2, conditioning period; T3, immunosuppressed period; T4, engraftment period; objective, data from actigraphy, subjective: data from ISI, ∗∗∗ P < 0.001.
| Variables | T2 | T3 | T4 | Sources | F | P |
| (Mean ± SD) | (Mean ± SD) | (Mean ± SD) | ||||
| Objective (h) | 4.28 ± 1.43 | 5.28 ± 1.41 | 5.33 ± 1.82 | Group | 0.674 | 0.414 |
| Subjective (h) | 3.86 ± 1.51 | 4.95 ± 1.38 | 5.45 ± 1.63 | Time | 24.668 | 0.000∗∗∗ |
| t ( P ) | 0.37 (0.709) | 1.78 (0.083) | 1.33 (0.998) | Group∗Time | 1.072 | 0.345 |
Comparison of objective and subjective sleep efficiency
The sleep efficiency results showed significant differences by period ( P = 0.001), and between objective and subjective data, even excluding the effect of time ( P < 0.001). The levels of objective and subjective sleep efficiency were found to be correlated with time and measurement method ( P = 0.002) ( Table 5 ; Fig. 1 ). Table 5 Repeated measures ANOVA of objective and subjective sleep efficiency ( n = 40). Table 5 Variables T2 T3 T4 Sources F P (Mean ± SD) (Mean ± SD) (Mean ± SD) Objective (%) 64.35 ± 11.38 77.28 ± 10.07 75.24 ± 10.44 Group 20.858 0.000∗∗∗ Subjective (%) 59.57 ± 22.67 57.07 ± 19.11 64.74 ± 18.99 Time 6.864 0.001 t ( P ) 1.95 (0.168) 2.65 (0.002) 2.17 (0.035) Group∗Time 6.284 0.002 T2, conditioning period; T3, immunosuppressed period; T4, engraftment period; objective, data from actigraphy, subjective, converted scores into percentage of revised ISI scores, ∗∗∗ P < 0.001.
Table 5
Repeated measures ANOVA of objective and subjective sleep efficiency ( n = 40).
T2, conditioning period; T3, immunosuppressed period; T4, engraftment period; objective, data from actigraphy, subjective, converted scores into percentage of revised ISI scores, ∗∗∗ P < 0.001.
| Variables | T2 | T3 | T4 | Sources | F | P |
| (Mean ± SD) | (Mean ± SD) | (Mean ± SD) | ||||
| Objective (%) | 64.35 ± 11.38 | 77.28 ± 10.07 | 75.24 ± 10.44 | Group | 20.858 | 0.000∗∗∗ |
| Subjective (%) | 59.57 ± 22.67 | 57.07 ± 19.11 | 64.74 ± 18.99 | Time | 6.864 | 0.001 |
| t ( P ) | 1.95 (0.168) | 2.65 (0.002) | 2.17 (0.035) | Group∗Time | 6.284 | 0.002 |
Discussion
This study was conducted with the goal of investigating objective and subjective sleep time and efficiency and their changes over four transplantation periods (pre-treatment [T1] and during treatment [T2-T4]) of patients hospitalized for HSCT and to evaluate the differences between the objective and subjective measures. The average objective daily sleep time of the participants was only 4.96 h (4 h and 57 min) and their average sleep efficiency was 72.29%. These results showed a comparatively lower average sleep time, but a higher sleep efficiency, than the values reported by Hacker et al (5.6 h and 55%, respectively). 7
According to the results of this study, both sleep time and efficiency demonstrated significant differences by period (T2-T4); in particular, less sleep time, lower efficiency, and more frequent WASO were observed at T2. This is most likely due to the increased need for urination from the large amount of IV fluids infused during T2. It should also be kept in mind that T2 is one of the earliest periods of treatment, and the unfamiliar devices and environment may have diminished the patients’ sleep quality; in other words, the possibility of the first-night effect cannot be ruled out.
Through this study, it was found that the subjective quality of sleep in hematopoietic stem cell transplant patients also deteriorated. Subjective sleep quality measurements using the ISI showed that 75% of the participants experienced some level of insomnia between subthreshold and moderate levels. This result corresponds with a preceding study that reported that 74% of HSCT patients demonstrated subjective sleep problems in subjective measurements. 6 Among the ISI items, participants found it most difficult to stay asleep and gave generally low scores for sleep satisfaction. This reflects the circumstances in which the participants were frequently interrupted during sleep by needing to urinate or being interrupted by visits from the medical staff after getting in bed, which also explains the high WASO time at every stage of the transplant process. The ISI scores showed significant gaps by period, as the reversed mean ISI score was 23.43 pre-hospitalization, indicating no insomnia, but the scores subsequently dropped to 16–18 during their hospital stay, indicating that they had subjective sleep problems.
Sleep time and efficiency showed different results depending on the measurement method. The sleep times measured by actigraphy and self-reported sleep times did not show significant differences in this study, unlike the significant gaps in sleep efficiency between actigraphy and ISI results. The gap between the objective and subjective measures of sleep efficiency was most prominent during the neutropenic period because actigraphy may have incorrectly recorded times when patients were simply laying and resting in bed as sleep, as actigraphy detects movement to determine the state of sleep. This result proves that there are limitations in measuring sleep efficiency using actigraphy, providing support for a preceding study suggesting that subjective and objective sleep quality were not significantly correlated in patients with anxiety and depression and that actigraphy was less sensitive in measuring sleep patterns of patients with socio-psychological symptoms. 18 Another study of patients with colorectal cancer prior to starting anti-cancer treatment suggested that objective and subjective measurements were not significantly correlated, as they represent different aspects of sleep, but concluded that taking both objective and subjective measurements is useful when evaluating sleep quality because subjective sleep problems are relevant to objective changes in the circadian rhythm. 19 As such, objective and subjective measurement methods may include different aspects of sleep, so they should be used as a way to complement each other.
This study found that most patients undergoing HSCT experienced objective and subjective sleep disorders during the transplantation period. More active and persistent interventions will be needed to improve the sleep quality of patients with HSCT. This study also confirmed that actigraphy, which determines sleep and awake states from the level of movement, may not always be reliable when used with hospitalized patients who spend most of their time lying in bed. Medical staff should keep in mind that patients lying in bed with their eyes closed may not always be asleep, especially during the neutropenic period. Measuring subjective sleep time and efficiency to complement actigraphy measures will help reduce potential errors.
While preceding studies of HSCT patients examined sleep patterns at only one point or cross-sectionally, the present study investigated sleep patterns using both objective and subjective methods in each transplantation period among participants who were admitted to the stem cell transplantation unit at the hospital on a long-term basis. It also provided significant findings for nursing professionals by identifying the severity of the sleep disruption suffered by patients with HSCT, underscoring the need for more active interventions. The results of this study have limitations in generalization as the participants were recruited by convenience sampling from a single tertiary hospital and the sample size was small. As a result of the analysis, there was no difference in sleep time and quality according to the type of room or transplant type, so it was not included in the results. However, if the number of subjects increases, different results may be shown, so the possibility of variables that can act as bias cannot be excluded.
Conclusions
The outcomes of this study demonstrated that a majority of the patients undergoing HSCT experienced significant decreases in sleep time during the transplantation period in both objective and subjective results. During the T3 period, where energy level of patients with HSCT is the lowest, actigraphy results falsely suggested high sleep efficiency by interpreting patients’ low movement state while awake as a sleep state, showing the largest gap between objective and subjective measurements. This result confirmed that actigraphy may misinterpret a low-energy state as sleep in patients who are receiving treatment for severe blood cancer.
Based on these findings, we propose that a new method that can measure sleep patterns without confusing a low-energy state for a sleep state should be developed and applied for patients with HSCT. Moreover, further research should be conducted with the goal of developing effective nursing interventions to enhance sleep efficiency in patients with severe blood cancer who are undergoing treatment.
Authors’ contributions
Conceived and designed the research: E. Suh, & M. Park.
Data collection: M. Park.
Data analysis: E. Suh, & M. Park.
Wrote the paper: E. Suh, & M. Park.
Declaration of competing interest
None declared.
Founding
Nil.
Ethics statement
This study was approved by the Ethics Board of Samsung Medical Center in Seoul (Approval 2019-05-014).
References
1 Friese R.S. Sleep and recovery from critical illness and injury: a review of theory, current practice, and future directions Crit Care Med 36 2008 697 705 18176314 10.1097/CCM.0B013E3181643F29
2 Hacker E.D. Patel P. Stainthorpe M. Sleep interrupted: nocturnal care disturbances Biol Blood Marrow Transplant 19 suppl 2 2013 S370 10.1188/13.CJON.517-523 24080050
3 Madsen M.T. Huang C. Gogenur I. Actigraphy for measurements of sleep in relation to oncological treatment of patients with cancer: a systematic review Sleep Med Rev 20 2015 73 83 25155183 10.1016/j.smrv.2014.07.002
4 Park H.R. Choi S.E. Park H.R. Park J.H. Moon Y.I. Sleep disturbance and related variables during hospitalization for hemopoietic stem cell transplantation Asian Oncol Nurs 5 2005 126 135
5 Jim H.S. Evans B. Jeong J.M. Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management Biol Blood Marrow Transplant 20 2014 1465 1484 24747335 10.1016/j.bbmt.2014.04.010 PMC4163090
6 Kim H.S. Lee S.S. Insomnia in patients with hematopoietic stem cell transplantation (HSCT) J Korean Soc Biol Ther Psychiatry 24 2018 142 155
7 Boonstra L. Harden K. Jarvis S. Sleep disturbance in hospitalized recipients of stem cell transplantation Clin J Oncol Nurs 15 2011 271 276 21624862 10.1188/11.CJON.271-276
8 Hacker E.D. Kapella M.C. Park C. Ferrans C.E. Larson J.L. Sleep patterns during hospitalization following hematopoietic stem cell transplantation Oncol Nurs Forum 42 2015 371 379 26148316 10.1188/15.ONF.371-379 PMC4547461
9 Cheung Y.T. Brinkman T.M. Mulrooney D.A. Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia Cancer 123 2017 3410 3419 28452142 10.1002/cncr.30742 PMC5570612
10 Nelson A.M. Coe C.L. Juckett M.B. Sleep quality following hematopoietic stem cell transplantation: longitudinal trajectories and biobehavioral correlates Bone Marrow Transplant 49 2014 1405 1411 25133898 10.1038/bmt.2014.179 PMC4221490
11 Seo S.Y. Subjective and Objective Assessment of Insomnia Disorder 2018 2018 Annual Conference of Korean Psychological Association 185
12 Ancoli-Israel S. Cole R. Alessi C. Chambers M. Moorcroft W. Pollak C.P. The role of actigraphy in the study of sleep and circadian rhythms Sleep 26 2003 342 392 12749557 10.1093/sleep/26.3.342
13 de Souza L. Benedito-Silva A.A. Nogueira Pires M.L. Further validation of actigraphy for sleep studies Sleep 26 1 2003 81 85 12627737 10.1093/sleep/26.1.81
14 Reed D.L. Sacco W.P. Measuring sleep efficiency: what should the denominator Be? J Clin Sleep Med 12 2016 263 266 26194727 10.5664/jcsm.5498 PMC4751425
15 Berger A.M. Parker K.P. Young-McCaughan S. Sleep wake disturbances in people with cancer and their caregivers: state of the science Oncol Nurs Forum 32 2005 E98 E126 16270104 10.1188/05.ONF.E98-E126
16 Seo H.J. Hong S.C. Actigraphy use in sleep disorders Korean J Psychopharmacol 21 2010 193 194
17 Cho Y.W. Song M.L. Morin C.M. Validation of a Korean version of the insomnia severity index J Clin Neurol 10 3 2014 210 215 25045373 10.3988/jcn.2014.10.3.210 PMC4101097
18 Klumpp H. Roberts J. Kapella M.C. Kennedy A.E. Kumar A. Phan K.L. Subjective and objective sleep quality modulate emotion regulatory brain function in anxiety and depression Depress Anxiety 34 2017 651 660 28419607 10.1002/da.22622 PMC5503154
19 Palesh O. Haitz K. Levi F. Relationship between subjective and actigraphy-measured sleep in 237 patients with metastatic colorectal cancer Qual Life Res 26 2017 2783 2791 28656534 10.1007/s11136-017-1617-2 PMC5711611